<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4">Pertussis</h1><h4 class="text-base font-semibold mt-4 mb-2"><strong>1 | Disease &amp; Natural History</strong></h4><ul><li><em>Bordetella pertussis</em> (rarely <em>B. parapertussis</em>, not vaccine‑preventable). Illness: catarrhal → paroxysmal cough/“whoop” lasting ≥2 – 3 m; apnoea common in infants .</li><li>Complications: bronchopneumonia, weight‑loss, cerebral hypoxia; deaths mainly in unvaccinated &lt;6 m .</li><li><strong>Incubation</strong> 6 – 20 d; infectious from day –6 of catarrhal phase to 3 w after paroxysms .</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>2 | UK Epidemiology &amp; Maternal‑programme Impact</strong></h4><table><tr><td><p><strong>Year / period</strong></p></td><td><p><strong>Key event</strong></p></td><td><p><strong>Lab‑confirmed cases</strong></p></td><td><p><strong>Infant deaths</strong></p></td></tr><tr><td><p>1950s (pre‑vax)</p></td><td><p>Baseline</p></td><td><p>&gt;120 000 / yr</p></td><td><p>100s</p></td></tr><tr><td><p>1978 (coverage ≈ 30 %)</p></td><td><p>Whole‑cell scare</p></td><td><p>65 000</p></td><td><p>12</p></td></tr><tr><td><p>2012 outbreak</p></td><td><p>Triggered antenatal programme</p></td><td><p>Surge</p></td><td><p>14 (2012)</p></td></tr><tr><td><p>2013‑Dec 2024</p></td><td><p>Maternal programme</p></td><td><p>Variable cyclical peaks; Q1 2024 &gt;2012</p></td><td><p><strong>31</strong> deaths (vs 63 in 12 y pre‑programme)</p></td></tr><tr><td><p>Maternal VE vs infant death <strong>91 % (95 % CI 73‑98 %)</strong> . Large 2024 surge attributed to post‑COVID immunity gap .</p></td><td></td><td></td><td></td></tr></table><h4 class="text-base font-semibold mt-4 mb-2"><strong>3 | Laboratory Diagnosis Timeline</strong></h4><p>Culture → enhanced surveillance 1994 → serology 2001 → PCR 2002 → oral‑fluid IgG (2‑16 y) 2013 .</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>4 | Vaccine Science &amp; Products</strong></h4><ul><li>UK uses <strong>acellular pertussis (aP)</strong> only; 3‑ vs 5‑component aP give similar efficacy .</li><li>Key combined products (0.5 ml IM):</li></ul><table><tr><td><p><strong>Group</strong></p></td><td><p><strong>Vaccine (manufacturer)</strong></p></td><td><p><strong>aP comps</strong></p></td><td><p><strong>Other antigens</strong></p></td><td><p><strong>Licensing / programme role</strong></p></td></tr><tr><td><p><strong>Primary &amp; 18 m</strong></p></td><td><p>Infanrix Hexa (GSK) – 3; Vaxelis (Sanofi) – 5</p></td><td><p>D,T (full), IPV, Hib, HepB</p></td><td><p>Inter‑changeable; prefer course continuity </p></td><td></td></tr><tr><td><p><strong>Pre‑school booster</strong></p></td><td><p>Repevax (5‑comp) / Boostrix‑IPV (3‑comp)</p></td><td><p>d,T (low), IPV</p></td><td><p>Both latex‑free; also maternal alt</p></td><td></td></tr><tr><td><p><strong>Maternal &amp; HCW</strong></p></td><td><p><strong>Adacel (Tdap, 5‑comp) – preferred</strong></p></td><td><p>d,T (low)</p></td><td><p>No IPV – avoids infant type‑2 polio blunting </p></td><td></td></tr></table><p><em>Latex allergy</em>: Adacel tip‑cap contains latex – use Repevax/Boostrix‑IPV in pregnancy .</p><p><strong>Composition tables</strong> (toxoid &amp; antigen µg/DU) are on pp 6‑8 – skim for viva .</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>5 | UK Immunisation Schedule (from Jul 2025)</strong></h4><ol><li><strong>Primary</strong> : 8‑, 12‑, 16‑wk DTaP/IPV/Hib/HepB ×3.</li><li><strong>18 m hexavalent booster</strong> (new) – maintains Hib; <strong>does not</strong> replace preschool booster .</li><li><strong>Pre‑school booster</strong> (3 y 4 m): dTaP/IPV .</li><li><strong>Maternal</strong> : Tdap each pregnancy, 16‑32 wk (target ≈ 20 wk); can give until labour or ≤8 wk postpartum for maternal protection .</li><li><strong>HCW booster</strong> : if ≥5 y since last aP and regular contact with pregnant women / infants &lt;3 m .</li><li><strong>Outbreak control</strong> : additional aP + macrolide PEP per UKHSA guidance .</li></ol><h4 class="text-base font-semibold mt-4 mb-2"><strong>6 | Special Groups &amp; Precautions</strong></h4><table><tr><td><p><strong>Situation</strong></p></td><td><p><strong>Key advice</strong></p></td><td><p><strong>Source</strong></p></td></tr><tr><td><p><strong>Premature ≤28 wk</strong></p></td><td><p>Vaccinate on time; observe 48‑72 h for apnoea </p></td><td><p>turn11file4</p></td></tr><tr><td><p><strong>Severe latex allergy (pregnancy)</strong></p></td><td><p>Offer dTaP/IPV, arrange referral if maternity stock absent </p></td><td><p>turn11file4</p></td></tr><tr><td><p><strong>Bleeding disorder</strong></p></td><td><p>Follow Ch 4 IM guidance; stable vs unstable distinction </p></td><td><p>turn11file15</p></td></tr><tr><td><p><strong>Immunosuppressed / HIV</strong></p></td><td><p>Give inactivated aP as scheduled; may revaccinate post‑therapy </p></td><td><p>turn11file3</p></td></tr></table><p>Minor illness, previous HHE, febrile convulsion = <em>not</em> contra‑indications .</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>7 | Co‑administration &amp; Blunting Issues</strong></h4><ul><li>Safe with influenza, COVID‑19 vaccines; do <strong>not</strong> give &lt;16 wk gestation .</li><li><strong>RSV vaccine:</strong> slight reduction in some pertussis antibody titres; preferable to separate (pertussis ~20 wk, RSV ≥28 wk) but may co‑administer if late .</li><li><strong>IPV blunting:</strong> infants of mothers vaccinated with IPV‑containing Tdap show reduced type 2 polio response; hence Adacel (no IPV) is preferred since Oct 2022 .</li><li>Hexavalent + PCV/MMR increases febrile convulsions – counsel parents .</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>8 | Occupational Vaccination (HCWs)</strong></h4><ul><li>Offer pertussis to HCWs without aP in last 5 y <strong>and</strong> regular contact with pregnant women or infants &lt;3 m.<ul><li><strong>Priority 1</strong>: maternity, neonatal &amp; paediatric ICUs .</li><li><strong>Priority 2</strong>: general paediatrics, specialised paediatric units, health visitors .</li></ul></li><li>Order vaccines direct from manufacturers / ImmForm; telephone &amp; web ordering details given .</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>9 | Supply, Storage &amp; Disposal</strong></h4><ul><li>National stock list includes Repevax, Boostrix‑IPV, Infanrix IPV+Hib, Infanrix Hexa, Vaxelis, Adacel .</li><li>Order via ImmForm (E, W, S) or NI holding centres .</li><li>Store 2–8 °C; dispose sharps per HTM 07‑01 .</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>10 | Adverse Events &amp; Reporting</strong></h4><p>Local pain/erythema common; systemic fever/irritability rare; aP safer than wP .</p><p> Report to MHRA Yellow Card (black‑triangle products or serious AE) .</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>11 | Management of Contacts &amp; Outbreaks</strong></h4><ul><li><strong>Notifiable disease</strong>.</li><li>Macrolide PEP (clarithro/azithro) + selective vaccination per UKHSA guidelines .</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>12 | Exam‑Focused Mnemonics</strong></h4><ul><li><strong>WHOOP 91</strong> – Waning immunity, HCW boosters, Outbreak cycles, Occupational vaccine, Polio blunting (Adacel), <strong>91 %</strong> maternal VE vs infant death.</li><li><strong>“8‑12‑16 / 18 / 3 + 4 / MAT‑20”</strong> – schedule line.</li><li><strong>“RSV after aP”</strong> – separate to avoid antibody attenuation.</li><li><strong>“5 years &amp; &lt;3 m”</strong> – HCW booster interval / infant age risk.</li></ul><p>These updated notes now incorporate:</p><ul><li><strong>Polio‑blunting rationale &amp; Adacel preference</strong> </li><li><strong>18‑month hexavalent booster &amp; five‑dose lifetime schedule</strong> </li><li><strong>Detailed HCW occupational offer &amp; priority groups</strong> </li><li><strong>Vaccine ordering, supply lists, disposal rules</strong> </li><li><strong>Co‑administration with RSV, flu, COVID‑19</strong> </li><li><strong>Prematurity, latex allergy, bleeding disorders</strong> </li><li><strong>All current product compositions &amp; interchangeability guidance</strong> </li></ul>
</div>